Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Drug Manufacturers — Specialty and Generic

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of epileptic seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The company`s proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation of epinephrine for the treatment of anaphylaxis; and AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly. It also develops APL-130277, a sublingual film formulation of apomorphine to treat Parkinson`s disease. Aquestive Therapeutics, Inc. was founded in 2004 and is headquartered in Warren, New Jersey.
Website: aquestive.com



Growth: Pretty weak revenue growth rate 7.7%, there is slowdown compared to average historical growth rates 11.3%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -32.2%. On average the margin is decreasing steadily. Gross margin is high, +67.2%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 100% of quarters (showing a gain of +$0.09 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 17.4% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 789.7% higher than minimum and 13.9% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 0.4x by EV / Sales multiple , the company can be 91.4% overvalued

Insiders: For the last 3 months insiders sold company shares on $0.7 mln (-0.180% of cap.)

Key Financials (Download financials)

Ticker: AQST
Share price, USD:  (0.0%)6.45
year average price 4.18  


year start price 3.13 2025-01-08

min close price 2.22 2025-05-14

max close price 7.49 2025-10-20

current price 6.45 2026-01-07
Common stocks: 54 390 696

Dividend Yield:  0.0%
EV / Sales: 5.3x
Margin (EBITDA LTM / Revenue): -32.2%
Fundamental value created in LTM:
Market Cap ($m): 351
Net Debt ($m): -41
EV (Enterprise Value): 310
Price to Book: -85.4x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-11-07seekingalpha.com

Aquestive Therapeutics, Inc. (AQST) Discusses Anaphylm Regulatory Progress, Commercial Strategy, and Pipeline Development Transcript

2025-11-05zacks.com

Aquestive Therapeutics (AQST) Reports Q3 Loss, Lags Revenue Estimates

2025-10-15zacks.com

Are Medical Stocks Lagging Aquestive Therapeutics (AQST) This Year?

2025-10-12seekingalpha.com

Aquestive Therapeutics: A Measured Bet

2025-09-22zacks.com

Aquestive Therapeutics (AQST) Soars 14.8%: Is Further Upside Left in the Stock?

2025-09-05seekingalpha.com

Aquestive Therapeutics: No AdCom For Anaphylm Derisks January Approval Catalyst

2025-08-14zacks.com

Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?

2025-08-14globenewswire.com

Aquestive Therapeutics Announces $75M Strategic Funding Agreement with RTW to Support the Potential Launch of Anaphylm™ (epinephrine) Sublingual Film

2025-08-12seekingalpha.com

Aquestive Therapeutics, Inc. (AQST) Q2 2025 Earnings Call Transcript

2025-08-11zacks.com

Compared to Estimates, Aquestive Therapeutics (AQST) Q2 Earnings: A Look at Key Metrics
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2025-09-30 2025-06-30 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol AQST AQST AQST AQST AQST AQST AQST AQST AQST AQST AQST AQST
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-05 2025-08-11 2024-11-04 2024-08-06 2024-05-07 2024-03-05 2023-11-06 2023-08-07 2023-05-02 2023-03-31 2022-11-01 2022-08-02
acceptedDate 2025-11-05 16:07:03 2025-08-11 16:11:29 2024-11-04 16:42:52 2024-08-06 16:26:06 2024-05-07 16:23:32 2024-03-05 17:12:49 2023-11-06 17:22:44 2023-08-07 16:54:49 2023-05-02 17:11:51 2023-03-31 16:31:41 2022-11-01 16:37:23 2022-08-02 16:22:03
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2023 2022 2022 2022
period Q3 Q2 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2
revenue 13M 10M 14M 20M 12M 13M 13M 13M 11M 11M 11M 13M
costOfRevenue 5M 5M 4M 5M 4M 5M 5M 7M 5M 5M 5M 5M
grossProfit 8M 5M 9M 16M 8M 9M 8M 7M 6M 5M 7M 8M
grossProfitRatio 0.648 0.544 0.672 0.775 0.636 0.646 0.631 0.5 0.575 0.503 0.597 0.605
researchAndDevelopmentExpenses 5M 4M 5M 4M 6M 3M 3M 3M 4M 4M 3M 5M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 15M 13M 12M 11M 11M 10M 7M 7M 7M 12M 12M 16M
otherExpenses 0 0 0 0 0 0 0 0 0 0 0 0
operatingExpenses 20M 17M 17M 16M 17M 12M 11M 11M 11M 16M 16M 21M
costAndExpenses 24M 21M 22M 20M 21M 17M 15M 17M 16M 21M 20M 26M
interestIncome 0 2M 979 000 1M 329 000 165 000 2M 129 000 15M 65 000 5000 32 000
interestExpense 4M 4M 4M 4M 4M 3M -1M 1M 1M 2M 4M 4M
depreciationAndAmortization 139 000 140 000 159 000 205 000 207 000 43 812 263 000 289 000 325 000 65 000 601 000 667 000
ebitda -11M -9M -7M 260 000 -9M -3M -2M -4M 10M -11M -8M -12M
ebitdaratio -0.862 -0.913 -0.528 0.013 -0.726 -0.261 -0.183 -0.286 0.89 -0.997 -0.72 -0.909
operatingIncome -11M -11M -8M 55 000 -9M -4M -2M -4M 10M -11M -9M -13M
operatingIncomeRatio -0.896 -1.136 -0.612 0.003 -0.743 -0.296 -0.183 -0.318 0.861 -1.003 -0.772 -0.962
totalOtherIncomeExpensesNet -4M -2M -3M -3M -4M -4M 202 000 -1M -2M -2M -4M -4M
incomeBeforeTax -15M -14M -12M -3M -13M -8M -2M -6M 8M -12M -13M -16M
incomeBeforeTaxRatio -1.206 -1.354 -0.85 -0.137 -1.064 -0.607 -0.167 -0.416 0.725 -1.156 -1.094 -1.229
incomeTaxExpense 0 0 0 0 163 724 101 000 -140 000 284 000 -11M 6M 4M 0
netIncome -15M -14M -12M -3M -13M -8M -2M -6M 19M -18M -16M -16M
netIncomeRatio -1.206 -1.354 -0.85 -0.137 -1.064 -0.614 -0.157 -0.437 1.734 -1.699 -1.415 -1.229
eps -0.14 -0.14 -0.13 -0.03 -0.17 -0.12 -0.032 -0.1 0.35 -0.37 -0.3 -0.36
epsdiluted -0.14 -0.14 -0.13 -0.03 -0.17 -0.12 -0.032 -0.1 0.26 -0.37 -0.3 -0.36
weightedAverageShsOut 111M 99M 91M 91M 74M 69M 65M 57M 56M 49M 53M 45M
weightedAverageShsOutDil 111M 99M 91M 91M 74M 69M 65M 57M 74M 49M 53M 45M
link Link Link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2025-09-30 2025-06-30 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol AQST AQST AQST AQST AQST AQST AQST AQST AQST AQST AQST AQST
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-05 2025-08-11 2024-11-04 2024-08-06 2024-05-07 2024-03-05 2023-11-06 2023-08-07 2023-05-02 2023-03-31 2022-11-01 2022-08-02
acceptedDate 2025-11-05 16:07:03 2025-08-11 16:11:29 2024-11-04 16:42:52 2024-08-06 16:26:06 2024-05-07 16:23:32 2024-03-05 17:12:49 2023-11-06 17:22:44 2023-08-07 16:54:49 2023-05-02 17:11:51 2023-03-31 16:31:41 2022-11-01 16:37:23 2022-08-02 16:22:03
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2023 2022 2022 2022
period Q3 Q2 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2
cashAndCashEquivalents 129M 61M 78M 90M 95M 24M 25M 22M 27M 27M 19M 18M
shortTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0
cashAndShortTermInvestments 129M 61M 78M 90M 95M 24M 25M 22M 27M 27M 19M 18M
netReceivables 12M 12M 10M 6M 8M 8M 9M 10M 8M 5M 11M 19M
inventory 8M 8M 7M 7M 8M 7M 7M 6M 7M 6M 7M 5M
otherCurrentAssets 3M 1M 2M 1M 2M 2M 2M 1M 2M 2M 2M 2M
totalCurrentAssets 152M 82M 97M 104M 113M 41M 42M 40M 44M 40M 38M 44M
propertyPlantEquipmentNet 9M 9M 9M 9M 9M 10M 10M 10M 10M 8M 6M 7M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 1M 1M 1M 1M 1M 1M 1M 25 000
goodwillAndIntangibleAssets 0 0 0 0 1M 1M 1M 1M 1M 1M 1M 25 000
longTermInvestments 2M 0 0 3M 4M 4M 4M 4M 0 0 0 0
taxAssets 0 0 0 0 -1 -1 -4M -4M 0 0 0 0
otherNonCurrentAssets 1M 3M 4M 1M 1M 1M 5M 5M 6M 6M 6M 6M
totalNonCurrentAssets 12M 12M 13M 14M 16M 16M 17M 17M 18M 16M 14M 13M
otherAssets 0 0 0 0 1 1 0 0 0 0 0 0
totalAssets 164M 94M 110M 118M 130M 57M 59M 57M 61M 56M 52M 56M
accountPayables 11M 12M 8M 6M 11M 9M 10M 11M 12M 10M 11M 9M
shortTermDebt 8M 4M 507 000 479 000 1M 2M 5M 19M 18M 19M 15M 11M
taxPayables 0 336 000 473 000 382 000 433 000 337 000 377 000 299 000 413 000 322 000 351 000 267 000
deferredRevenue 1M 1M 1M 1M 2M 2M 3M 4M 5M 2M 774 000 2M
otherCurrentLiabilities 5M 6M 6M 6M 5M 5M 6M 5M 6M 9M 10M 8M
totalCurrentLiabilities 26M 23M 15M 14M 18M 18M 24M 39M 40M 40M 37M 30M
longTermDebt 120M 37M 36M 35M 109M 91M 40M 26M 31M 37M 40M 45M
deferredRevenueNonCurrent 20M 20M 20M 22M 32M 32M 33M 33M 33M 31M 18M 13M
deferredTaxLiabilitiesNonCurrent 0 0 0 5M 5M 5M 64M 63M 0 0 0 0
otherNonCurrentLiabilities 2M 87M 84M 82M 2M 17M 2M 2M 66M 66M 96M 64M
totalNonCurrentLiabilities 142M 143M 140M 139M 148M 146M 138M 125M 130M 135M 123M 123M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 5M 5M 6M 6M 5M 5M 6M 6M 6M 4M 2M 2M
totalLiabilities 168M 166M 155M 153M 166M 164M 162M 164M 171M 174M 160M 153M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 121 000 99 000 91 000 91 000 90 000 69 000 67 000 62 000 56 000 55 000 54 000 53 000
retainedEarnings -415M -400M -346M -335M -332M -319M -311M -309M -303M -311M -299M -286M
accumulatedOtherComprehensiveIncomeLoss 0 0 0 0 -0 0 0 0 0 0 0 0
othertotalStockholdersEquity 411M 327M 301M 299M 296M 213M 208M 202M 194M 193M 191M 190M
totalStockholdersEquity -4M -73M -45M -35M -36M -106M -103M -107M -109M -119M -108M -96M
totalEquity -4M -73M -45M -35M -36M -106M -103M -107M -109M -119M -108M -96M
totalLiabilitiesAndStockholdersEquity 164M 94M 110M 118M 130M 57M 59M 57M 61M 56M 52M 56M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 164M 94M 110M 118M 130M 57M 59M 57M 61M 56M 52M 56M
totalInvestments 2M 0 3M 3M 4M 4M 4M 4M 0 0 0 0
totalDebt 129M 40M 37M 117M 115M 99M 45M 45M 48M 56M 55M 56M
netDebt -200 999 -20M -41M 27M 20M 75M 20M 23M 22M 29M 36M 38M
link Link Link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2025-09-30 2025-06-30 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol AQST AQST AQST AQST AQST AQST AQST AQST AQST AQST AQST AQST
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-05 2025-08-11 2024-11-04 2024-08-06 2024-05-07 2024-03-05 2023-11-06 2023-08-07 2023-05-02 2023-03-31 2022-11-01 2022-08-02
acceptedDate 2025-11-05 16:07:03 2025-08-11 16:11:29 2024-11-04 16:42:52 2024-08-06 16:26:06 2024-05-07 16:23:32 2024-03-05 17:12:49 2023-11-06 17:22:44 2023-08-07 16:54:49 2023-05-02 17:11:51 2023-03-31 16:31:41 2022-11-01 16:37:23 2022-08-02 16:22:03
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2023 2022 2022 2022
period Q3 Q2 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2
netIncome -15M -14M -12M -3M -13M -8M -2M -6M 8M -12M -13M -16M
depreciationAndAmortization 139 000 140 000 159 000 205 000 207 000 467 000 263 000 289 000 325 000 397 000 596 000 667 000
deferredIncomeTax 0 0 0 0 0 -3M 0 0 0 0 0 0
stockBasedCompensation 3M 2M 2M 2M 2M 940 000 774 000 631 000 344 000 714 000 535 000 2M
changeInWorkingCapital -3M 919 000 -5M -8M -2M -1M -1M -3M 283 000 20M 12M 5M
accountsReceivables 63 000 -1M -2M 2M 147 000 104 000 2M -2M 0 0 0 0
inventory 241 000 -927 000 -55 000 768 000 -965 000 310 000 -1M 1M -1M 944 000 -2M -379 000
accountsPayables -1M -323 000 2M -3M 1M -1M -695 000 -2M 2M -1M 2M 392 000
otherWorkingCapital -2M 4M -4M -8M -3M -446 000 -2M -692 000 -1M 20M 12M -400 000
otherNonCashItems 3M 3M 3M 4M 4M 5M 88 000 52 000 -204 000 -54 000 2M 2M
netCashProvidedByOperatingActivities -13M -8M -12M -7M -10M -5M -2M -8M 9M 8M 3M -7M
investmentsInPropertyPlantAndEquipment -235 000 -107 000 -80 000 -35 000 -29 000 -16 000 -151 000 -826 000 -2000 -26 000 -2M 0
acquisitionsNet 0 0 0 0 0 0 0 0 0 0 0 0
purchasesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0
otherInvestingActivites 0 0 0 -35 000 0 0 0 0 0 0 -2M -677 000
netCashUsedForInvestingActivites -235 000 -107 000 -80 000 -35 000 -29 000 -16 000 -151 000 -826 000 -2000 -26 000 -2M -677 000
debtRepayment -7000 -8000 -8000 -5000 -5000 -15M -1M -4M -9M -675 000 -675 000 0
commonStockIssued 80M -124 000 0 2M 83M 4M 184 000 4M 916 000 7M 544 000 5M
commonStockRepurchased 0 0 898 000 0 -893 000 11 000 0 -3000 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 -3000 0 0 0 0
otherFinancingActivites 2M 32 000 -202 000 25 000 -893 000 15M 6M 5M -1M -6M -7000 5M
netCashUsedProvidedByFinancingActivities 81M -100 000 -17 000 2M 82M 4M 5M 4M -9M 204 000 -138 000 10M
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 0 0 0 0
netChangeInCash 69M -8M -12M -5M 71M -1M 2M -4M -391 000 9M 954 000 3M
cashAtEndOfPeriod 129M 61M 78M 90M 95M 24M 25M 22M 27M 27M 19M 18M
cashAtBeginningOfPeriod 61M 69M 90M 95M 24M 25M 22M 27M 27M 19M 18M 15M
operatingCashFlow -13M -8M -12M -7M -10M -5M -2M -8M 9M 8M 3M -7M
capitalExpenditure -235 000 -107 000 -80 000 -35 000 -29 000 -16 000 -151 000 -826 000 -2000 -26 000 -2M -677 000
freeCashFlow -13M -8M -12M -7M -10M -5M -2M -9M 9M 8M 1M -7M
link Link Link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link Link Link

Earning call transcript

2025 q3
2025-11-06 ET (fiscal 2025 q3)
2025 q2
2025-08-12 ET (fiscal 2025 q2)
2025 q1
2025-05-13 ET (fiscal 2025 q1)
2024 q4
2025-03-06 ET (fiscal 2024 q4)
2024 q3
2024-11-05 ET (fiscal 2024 q3)
2024 q2
2024-08-07 ET (fiscal 2024 q2)
2024 q1
2024-05-08 ET (fiscal 2024 q1)
2023 q4
2024-03-06 ET (fiscal 2023 q4)
2023 q3
2023-11-07 ET (fiscal 2023 q3)
2023 q2
2023-08-08 ET (fiscal 2023 q2)
2023 q1
2023-05-03 ET (fiscal 2023 q1)
2022 q4
2023-03-08 ET (fiscal 2022 q4)
2022 q3
2022-11-02 ET (fiscal 2022 q3)
2022 q2
2022-08-03 ET (fiscal 2022 q2)
2022 q1
2022-05-04 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 8
2025-11-06 21:01 ET
Aquestive Therapeutics published news for 2025 q3
SEC form 8
2025-11-06 21:01 ET
Aquestive Therapeutics published news for 2025 q3
SEC form 10
2025-11-05 16:07 ET
Aquestive Therapeutics reported for 2025 q3
SEC form 8
2025-11-05 16:04 ET
Aquestive Therapeutics published news for 2025 q3
SEC form 8
2025-11-05 16:04 ET
Aquestive Therapeutics reported for 2025 q3
SEC form 8
2025-11-05 16:04 ET
Aquestive Therapeutics published news for 2025 q3
SEC form 8
2025-10-08 11:23 ET
Aquestive Therapeutics published news for 2025 q3
SEC form 8
2025-10-08 11:23 ET
Aquestive Therapeutics published news for 2025 q3
SEC form 8
2025-10-01 12:41 ET
Aquestive Therapeutics published news for 2025 q3
SEC form 8
2025-10-01 12:41 ET
Aquestive Therapeutics published news for 2025 q3
SEC form 8
2025-09-08 12:32 ET
Aquestive Therapeutics published news for 2025 q2
SEC form 8
2025-09-08 12:32 ET
Aquestive Therapeutics published news for 2025 q2
SEC form 8
2025-09-04 11:11 ET
Aquestive Therapeutics published news for 2025 q2
SEC form 8
2025-09-04 11:11 ET
Aquestive Therapeutics published news for 2025 q2
SEC form 8
2025-08-15 01:37 ET
Aquestive Therapeutics published news for 2025 q2
SEC form 8
2025-08-15 01:37 ET
Aquestive Therapeutics published news for 2025 q2
SEC form 8
2025-08-15 01:37 ET
Aquestive Therapeutics published news for 2025 q2
SEC form 8
2025-08-15 01:37 ET
Aquestive Therapeutics published news for 2025 q2
SEC form 8
2025-08-15 01:37 ET
Aquestive Therapeutics published news for 2025 q2
SEC form 8
2025-08-14 10:26 ET
Aquestive Therapeutics published news for 2025 q2
SEC form 8
2025-08-14 10:26 ET
Aquestive Therapeutics published news for 2025 q2
SEC form 10
2025-08-11 20:11 ET
Aquestive Therapeutics reported for 2025 q2
SEC form 8
2025-08-11 20:05 ET
Aquestive Therapeutics published news for 2025 q2
SEC form 8
2025-08-11 20:05 ET
Aquestive Therapeutics published news for 2025 q2
SEC form 8
2025-08-11 20:05 ET
Aquestive Therapeutics published news for 2025 q2
SEC form 8
2025-08-11 20:05 ET
Aquestive Therapeutics reported for 2025 q2
SEC form 8
2025-07-15 11:54 ET
Aquestive Therapeutics published news for 2025 q2
SEC form 8
2025-07-15 11:54 ET
Aquestive Therapeutics published news for 2025 q2
SEC form 8
2025-06-16 11:48 ET
Aquestive Therapeutics published news for 2025 q1
SEC form 8
2025-06-16 11:48 ET
Aquestive Therapeutics published news for 2025 q1
SEC form 8
2025-06-02 20:03 ET
Aquestive Therapeutics published news for 2025 q1
SEC form 8
2025-06-02 20:03 ET
Aquestive Therapeutics published news for 2025 q1
SEC form 10
2025-05-12 20:07 ET
Aquestive Therapeutics reported for 2025 q1
SEC form 8
2025-05-12 20:05 ET
Aquestive Therapeutics reported for 2025 q1
SEC form 8
2025-05-12 20:05 ET
Aquestive Therapeutics published news for 2025 q1
SEC form 8
2025-05-12 20:05 ET
Aquestive Therapeutics published news for 2025 q1
SEC form 10
2025-05-12 00:00 ET
Aquestive Therapeutics reported for 2025 q1
SEC form 8
2025-04-01 12:26 ET
Aquestive Therapeutics published news for 2025 q1
SEC form 8
2025-04-01 12:26 ET
Aquestive Therapeutics published news for 2025 q1
SEC form 8
2025-03-10 12:10 ET
Aquestive Therapeutics published news for 2024 q4
SEC form 8
2025-03-10 12:10 ET
Aquestive Therapeutics published news for 2024 q4
SEC form 10
2025-03-05 16:29 ET
Aquestive Therapeutics reported for 2024 q4
SEC form 8
2025-03-05 16:13 ET
Aquestive Therapeutics published news for 2024 q4
SEC form 8
2025-03-05 16:13 ET
Aquestive Therapeutics reported for 2024 q4
SEC form 8
2025-03-05 16:13 ET
Aquestive Therapeutics published news for 2024 q4
SEC form 10
2025-03-05 00:00 ET
Aquestive Therapeutics reported for 2024 q4
SEC form 8
2025-02-12 12:22 ET
Aquestive Therapeutics published news for 2024 q4
SEC form 8
2025-02-12 12:22 ET
Aquestive Therapeutics published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Aquestive Therapeutics published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Aquestive Therapeutics published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Aquestive Therapeutics published news for 2024 q4
SEC form 10
2024-11-04 16:42 ET
Aquestive Therapeutics reported for 2024 q3
SEC form 8
2024-11-04 16:40 ET
Aquestive Therapeutics published news for 2024 q3
SEC form 8
2024-11-04 16:40 ET
Aquestive Therapeutics published news for 2024 q3
SEC form 8
2024-11-04 16:40 ET
Aquestive Therapeutics reported for 2024 q3
SEC form 10
2024-08-06 16:26 ET
Aquestive Therapeutics reported for 2024 q2
SEC form 8
2024-08-06 16:24 ET
Aquestive Therapeutics published news for 2024 q2
SEC form 8
2024-08-06 16:24 ET
Aquestive Therapeutics reported for 2024 q2
SEC form 8
2024-08-06 16:24 ET
Aquestive Therapeutics published news for 2024 q2
SEC form 10
2024-08-06 00:00 ET
Aquestive Therapeutics reported for 2024 q2
SEC form 10
2024-05-07 16:23 ET
Aquestive Therapeutics reported for 2024 q1
SEC form 8
2024-05-07 16:21 ET
Aquestive Therapeutics published news for 2024 q1
SEC form 8
2024-05-07 16:21 ET
Aquestive Therapeutics reported for 2024 q1
SEC form 8
2024-05-07 16:21 ET
Aquestive Therapeutics published news for 2024 q1
SEC form 10
2024-05-07 00:00 ET
Aquestive Therapeutics reported for 2024 q1
SEC form 10
2024-03-05 17:12 ET
Aquestive Therapeutics reported for 2023 q4
SEC form 8
2024-03-05 17:09 ET
Aquestive Therapeutics published news for 2023 q4
SEC form 8
2024-03-05 17:09 ET
Aquestive Therapeutics reported for 2023 q4
SEC form 8
2024-03-05 17:09 ET
Aquestive Therapeutics published news for 2023 q4
SEC form 10
2024-03-05 00:00 ET
Aquestive Therapeutics reported for 2023 q4
SEC form 10
2023-11-06 17:22 ET
Aquestive Therapeutics reported for 2023 q3
SEC form 8
2023-11-06 17:20 ET
Aquestive Therapeutics reported for 2023 q3
SEC form 10
2023-11-06 00:00 ET
Aquestive Therapeutics reported for 2023 q3
SEC form 6
2023-08-07 17:08 ET
Aquestive Therapeutics published news for 2023 q2
SEC form 10
2023-08-07 16:54 ET
Aquestive Therapeutics reported for 2023 q2
SEC form 8
2023-08-07 00:00 ET
Aquestive Therapeutics published news for 2023 q2
SEC form 10
2023-08-07 00:00 ET
Aquestive Therapeutics reported for 2023 q2
SEC form 6
2023-08-02 08:22 ET
Aquestive Therapeutics published news for 2023 q2
SEC form 6
2023-07-27 09:23 ET
Aquestive Therapeutics published news for 2023 q2
SEC form 6
2023-06-29 09:05 ET
Aquestive Therapeutics published news for 2023 q1
SEC form 6
2023-06-23 09:54 ET
Aquestive Therapeutics published news for 2023 q1
SEC form 6
2023-05-31 09:06 ET
Aquestive Therapeutics published news for 2023 q1
SEC form 8
2023-05-02 00:00 ET
Aquestive Therapeutics published news for 2023 q1
SEC form 10
2023-05-02 00:00 ET
Aquestive Therapeutics published news for 2023 q1
SEC form 6
2023-04-28 16:55 ET
Aquestive Therapeutics published news for 2023 q1
SEC form 6
2023-04-18 08:50 ET
Aquestive Therapeutics published news for 2023 q1
SEC form 10
2023-03-31 00:00 ET
Aquestive Therapeutics reported for 2022 q4
SEC form 8
2023-03-07 00:00 ET
Aquestive Therapeutics reported for 2022 q4
SEC form 10
2022-11-01 00:00 ET
Aquestive Therapeutics reported for 2022 q3
SEC form 8
2022-11-01 00:00 ET
Aquestive Therapeutics reported for 2022 q3
SEC form 10
2022-08-02 00:00 ET
Aquestive Therapeutics reported for 2022 q2
SEC form 8
2022-08-02 00:00 ET
Aquestive Therapeutics reported for 2022 q2
SEC form 10
2022-05-04 00:00 ET
Aquestive Therapeutics reported for 2022 q1
SEC form 8
2022-05-04 00:00 ET
Aquestive Therapeutics reported for 2022 q1
SEC form 10
2022-03-08 00:00 ET
Aquestive Therapeutics published news for 2021 q4
SEC form 8
2022-03-08 00:00 ET
Aquestive Therapeutics published news for 2021 q4
SEC form 10
2021-11-02 00:00 ET
Aquestive Therapeutics published news for 2021 q3
SEC form 8
2021-11-02 00:00 ET
Aquestive Therapeutics published news for 2021 q3
SEC form 10
2021-08-03 00:00 ET
Aquestive Therapeutics published news for 2021 q2
SEC form 10
2021-05-04 00:00 ET
Aquestive Therapeutics published news for 2021 q1